EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

A PI3K gene expression signature predicts for recurrence in early‐stage non–small cell lung cancer treated with stereotactic body radiation therapy

Nikhil T Sebastian iD, Amy Webb, Konstantin Shilo, Ryan Robb, Meng Xu-Welliver, Karl Haglund, Jeremy Brownstein, Gina M DeNicola, Changxian Shen, Terence M Williams

Cancer · 2023

DOI: 10.1002/cncr.34983 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2023. Verfasst von Nikhil T Sebastian und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Emory University, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Radiosurgery, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Increasingly, early‐stage non–small cell lung cancer (NSCLC) is treated with stereotactic body radiation therapy (SBRT). Although treatment is generally effective, a small subset of tumors will recur because of radioresistance. Preclinical studies suggested PI3K‐AKT‐mTOR activation mediates radioresistance. This study sought to validate this finding in tumor samples from patients who underwent SBRT for NSCLC.

Methods

Patients with T1‐3N0 NSCLC treated with SBRT at our institution were included. Total RNA of formalin‐fixed paraffin‐embedded tumor biopsy specimens (pretherapy) was isolated and analyzed using the Clariom D assay. Risk scores from a PI3K activity signature and four published NSCLC signatures were generated and dichotomized by the median. Kaplan–Meier curves and Cox regressions were used to analyze their association with recurrence and overall survival (OS). The PI3K signature was also tested in a data set of resected NSCLC for additional validation.

Results

A total of 92 patients were included, with a median follow‐up of 18.3 months for living patients. There was no association of any of the four published gene expression signatures with recurrence or OS. However, high PI3K risk score was associated with higher local recurrence (hazard ratio [HR], 11.72; 95% CI, 1.40–98.0; p = .023) and worse disease‐free survival (DFS) (HR, 3.98; 95% CI, 1.57–10.09; p = .0035), but not OS ( p = .49), regional recurrence ( p = .15), or distant recurrence ( p = .85). In the resected NSCLC data set ( n = 361), high PI3K risk score was associated with decreased OS (log‐rank p = .013) but not DFS ( p = 0.54).

Conclusions

This study validates that higher PI3K activity, measured by gene expression, is associated with local recurrence and worse DFS in early‐stage NSCLC patients treated with SBRT. This may be useful in prognostication and/or tailoring treatment, and merits further validation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsRadiosurgerySmall Cell Lung CarcinomaHumansNeoplasm StagingPhosphatidylinositol 3-KinasesRetrospective StudiesTranscriptomeTreatment OutcomeClass I Phosphatidylinositol 3-Kinases

Stichwörter der Autor:innen

PI3Kgene expressionnon-small cell lung cancerstereotactic body radiation therapy

Substanzen

Phosphatidylinositol 3-KinasesPIK3CD protein, humanClass I Phosphatidylinositol 3-Kinases

Autor:innen und Institutionen

  • Department of Radiation Oncology, Emory University, Atlanta, Georgia, USA.
  • Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio, USA.
  • Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
  • Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.

ORCID-Profile: Nikhil T Sebastian

Förderung

  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Sebastian, N. T., Webb, A., Shilo, K., Robb, R., Xu-Welliver, M., Haglund, K., Brownstein, J., DeNicola, G. M., Shen, C., & Williams, T. M. (2023). A PI3K gene expression signature predicts for recurrence in early‐stage non–small cell lung cancer treated with stereotactic body radiation therapy. Cancer. https://doi.org/10.1002/cncr.34983

Vancouver

Sebastian NT, Webb A, Shilo K, Robb R, Xu-Welliver M, Haglund K, et al. A PI3K gene expression signature predicts for recurrence in early‐stage non–small cell lung cancer treated with stereotactic body radiation therapy. Cancer. 2023. doi:10.1002/cncr.34983

BibTeX
@article{Sebastian2023,
  author = {Sebastian, Nikhil T and Webb, Amy and Shilo, Konstantin and Robb, Ryan and Xu-Welliver, Meng and Haglund, Karl and Brownstein, Jeremy and DeNicola, Gina M and Shen, Changxian and Williams, Terence M},
  title = {A PI3K gene expression signature predicts for recurrence in early‐stage non–small cell lung cancer treated with stereotactic body radiation therapy},
  journal = {Cancer},
  year = {2023},
  doi = {10.1002/cncr.34983}
}
Kostenlos starten →